Abstract
Background
The therapeutic potential of bacteriophages has been debated since their first isolation and characterisation in the early 20th century. However, a lack of consistency in application and observed efficacy during their early use meant that upon the discovery of antibiotic compounds research in the field of phage therapy quickly slowed. The rise of antibiotic resistance in bacteria and improvements in our abilities to modify and manipulate DNA, especially in the context of small viral genomes, has led to a recent resurgence of interest in utilising phage as antimicrobial therapeutics.
Results
In this article a number of results from the literature that have aimed to address key issues regarding the utility and efficacy of phage as antimicrobial therapeutics utilising molecular biology and synthetic biology approaches will be introduced and discussed, giving a general view of the recent progress in the field.
Conclusions
Advances in molecular biology and synthetic biology have enabled rapid progress in the field of phage engineering, with this article highlighting a number of promising strategies developed to optimise phages for the treatment of bacterial disease. Whilst many of the same issues that have historically limited the use of phages as therapeutics still exist, these modifications, or combinations thereof, may form a basis upon which future advances can be built. A focus on rigorous in vivo testing and investment in clinical trials for promising candidate phages may be required for the field to truly mature, but there is renewed hope that the potential benefits of phage therapy may finally be realised.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Summers, W. C. (2012) The strange history of phage therapy. Bacteriophage, 2, 130–133
Twort, F.W. (1915) An investigation on the nature of ultra-microscopic viruses. Lancet, 186, 1241–1243
d’Herelle, F. (1917) On an invisible microbe antagonistic to dysentery bacili. CR Acad. Sci. Paris, 165, 373–375
Abedon, S. T., Kuhl, S. J., Blasdel, B. G. and Kutter, E. M. (2011) Phage treatment of human infections. Bacteriophage, 1, 66–85
Neu, H. C. (1992) The crisis in antibiotic resistance. Science, 257, 1064–1073
Davies, J. and Davies, D. (2010) Origins and evolution of antibiotic resistance. Microbiol. Mol. Biol. Rev., 74, 417–433
Bradley, R. W., Buck, M. and Wang, B. (2016) Tools and principles for microbial gene circuit engineering. J. Mol. Biol., 428, 862–888
Wang, B. and Buck, M. (2012) Customizing cell signaling using engineered genetic logic circuits. Trends Microbiol., 20, 376–384
Wang, B., Kitney, R. I., Joly, N. and Buck, M. (2011) Engineering modular and orthogonal genetic logic gates for robust digital-like synthetic biology. Nat. Commun., 2, 508
Wang, B., Barahona, M. and Buck, M. (2013) A modular cell-based biosensor using engineered genetic logic circuits to detect and integrate multiple environmental signals. Biosens. Bioelectron., 40, 368–376
Bradley, R. W. and Wang, B. (2015) Designer cell signal processing circuits for biotechnology. N. Biotechnol., 32, 635–643
Haellman, V. and Fussenegger, M. (2016) Synthetic biology—toward therapeutic solutions. J. Mol. Biol., 428, 945–962
Smith, H. O., Hutchison, C. A. III, Pfannkoch, C. and Venter, J. C. (2003) Generating a synthetic genome by whole genome assembly: ΦX174 bacteriophage from synthetic oligonucleotides. Proc. Natl. Acad. Sci. USA, 100, 15440–15445
Chan, L.Y., Kosuri, S., and Endy, D. (2005) Refactoring bacteriophage T7. Mol. Syst. Biol. 1, 2005. 0018
Lu, T. K. and Koeris, M. S. (2011) The next generation of bacteriophage therapy. Curr. Opin. Microbiol., 14, 524–531
Pires, D. P., Cleto, S., Sillankorva, S., Azeredo, J. and Lu, T. K. (2016) Genetically engineered phages: a review of advances over the last decade. Microbiol. Mol. Biol. Rev., 80, 523–543
Rakhuba, D. V., Kolomiets, E. I., Dey, E. S. and Novik, G. I. (2010) Bacteriophage receptors, mechanisms of phage adsorption and penetration into host cell. Pol. J. Microbiol., 59, 145–155
Crawford, J. T. and Goldberg, E. B. (1977) The effect of baseplate mutations on the requirement for tail-fiber binding for irreversible adsorption of bacteriophage T4. J. Mol. Biol., 111, 305–313
Crawford, J. T. and Goldberg, E. B. (1980) The function of tail fibers in triggering baseplate expansion of bacteriophage T4. J. Mol. Biol., 139, 679–690
Arscott, P. G. and Goldberg, E. B. (1976) Cooperative action of the T4 tail fibers and baseplate in triggering conformational change and in determining host range. Virology, 69, 15–22
Molineux, I. J. (2001) No syringes please, ejection of phage T7 DNA from the virion is enzyme driven. Mol. Microbiol., 40, 1–8
Kemp, P., Garcia, L. R. and Molineux, I. J. (2005) Changes in bacteriophage T7 virion structure at the initiation of infection. Virology, 340, 307–317
Heller, K. and Braun, V. (1979) Accelerated adsorption of bacteriophage T5 to Escherichia coli F, resulting from reversible tail fiberlipopolysaccharide binding. J. Bacteriol., 139, 32–38
Heller, K. and Braun, V. (1982) Polymannose O-antigens of Escherichia coli, the binding sites for the reversible adsorption of bacteriophage T5+ via the L-shaped tail fibers. J. Virol., 41, 222–227
Riede, I., Degen, M. and Henning, U. (1985) The receptor specificity of bacteriophages can be determined by a tail fiber modifying protein. EMBO J., 4, 2343–2346
Montag, D., Riede, I., Eschbach, M.-L., Degen, M. and Henning, U. (1987) Receptor-recognizing proteins of T-even type bacteriophages: constant and hypervariable regions and an unusual case of evolution. J. Mol. Biol., 196, 165–174
Moody, M. F. (1973) Sheath of bacteriophage T4: III. contraction mechanism deduced from partially contracted sheaths. J. Mol. Biol., 80, 613–635
Wright, A., Hawkins, C. H., Änggård, E. E. and Harper, D. R. (2009) A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol., 34, 349–357
Gu, J., Liu, X., Li, Y., Han, W., Lei, L., Yang, Y., Zhao, H., Gao, Y., Song, J., Lu, R., et al. (2012) A method for generation phage cocktail with great therapeutic potential. PLoS One, 7, e31698
Oliveira, A., Sereno, R. and Azeredo, J. (2010) In vivo efficiency evaluation of a phage cocktail in controlling severe colibacillosis in confined conditions and experimental poultry houses. Vet. Microbiol., 146, 303–308
Jaiswal, A., Koley, H., Ghosh, A., Palit, A. and Sarkar, B. (2013) Efficacy of cocktail phage therapy in treating Vibrio cholerae infection in rabbit model. Microbes Infect., 15, 152–156
Chan, B. K. and Abedon, S. T. (2012). Chapter 1–Phage therapy pharmacology: phage cocktails. In Advances in Applied Microbiology, Laskin, A.I., Sariaslani, S. and Gadd, G.M. ed. 1–23. Massachusetts: Academic Press
Chan, B. K., Abedon, S. T. and Loc-Carrillo, C. (2013) Phage cocktails and the future of phage therapy. Future Microbiol., 8, 769–783
Gill, J. J. and Hyman, P. (2010) Phage choice, isolation, and preparation for phage therapy. Curr. Pharm. Biotechnol., 11, 2–14
Merabishvili, M., Pirnay, J.-P., Verbeken, G., Chanishvili, N., Tediashvili, M., Lashkhi, N., Glonti, T., Krylov, V., Mast, J., Van Parys, L., et al. (2009) Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One, 4, e4944
Kutter, E., De Vos, D., Gvasalia, G., Alavidze, Z., Gogokhia, L., Kuhl, S. and Abedon, S. T. (2010) Phage therapy in clinical practice: treatment of human infections. Curr. Pharm. Biotechnol., 11, 69–86
Mahichi, F., Synnott, A. J., Yamamichi, K., Osada, T. and Tanji, Y. (2009) Site-specific recombination of T2 phage using IP008 long tail fiber genes provides a targeted method for expanding host range while retaining lytic activity. FEMS Microbiol. Lett., 295, 211–217
Yoichi, M., Abe, M., Miyanaga, K., Unno, H. and Tanji, Y. (2005) Alteration of tail fiber protein gp38 enables T2 phage to infect Escherichia coli O157:H7. J. Biotechnol., 115, 101–107
Pouillot, F., Blois, H. and Iris, F. (2010) Genetically engineered virulent phage banks in the detection and control of emergent pathogenic bacteria. Biosecur. Bioterror., 8, 155–169
Krüger, D. H. and Schroeder, C. (1981) Bacteriophage T3 and bacteriophage T7 virus-host cell interactions. Microbiol. Rev., 45, 9–51
Lin, T.-Y., Lo, Y.-H., Tseng, P.-W., Chang, S.-F., Lin, Y.-T. and Chen, T.-S. (2012) A T3 and T7 recombinant phage acquires efficient adsorption and a broader host range. PLoS One, 7, e30954
Ando, H., Lemire, S., Pires, D. P. and Lu, T. K. (2015) Engineering modular viral scaffolds for targeted bacterial population editing. Cell Syst., 1, 187–196
Friedman, D. I. (1992) Interaction between bacteriophage l and its Escherichia coli host. Curr. Opin. Genet. Dev., 2, 727–738
Casjens, S. R., Gilcrease, E. B., Winn-Stapley, D. A., Schicklmaier, P., Schmieger, H., Pedulla, M. L., Ford, M. E., Houtz, J. M., Hatfull, G. F. and Hendrix, R. W. (2005) The generalized transducing Salmonella bacteriophage ES18: complete genome sequence and DNA packaging strategy. J. Bacteriol., 187, 1091–1104
Casjens, S. (2003) Prophages and bacterial genomics: what have we learned so far? Mol. Microbiol., 49, 277–300
Esvelt, K. M., Carlson, J. C. and Liu, D. R. (2011) A system for the continuous directed evolution of biomolecules. Nature, 472, 499–503
Bassalo, M. C., Liu, R. and Gill, R. T. (2016) Directed evolution and synthetic biology applications to microbial systems. Curr. Opin. Biotechnol., 39, 126–133
Prins, J. M., van Deventer, S. J., Kuijper, E. J. and Speelman, P. (1994) Clinical relevance of antibiotic-induced endotoxin release. Antimicrob. Agents Chemother., 38, 1211–1218
Slopek, S., Durlakowa, I., Weber-Dabrowska, B., Kucharewicz-Krukowska, A., Dabrowski, M. and Bisikiewicz, R. (1983) Results of bacteriophage treatment of suppurative bacterial infections. I. General evaluation of the results. Arch. Immunol. Ther. Exp. (Warsz.), 31, 267–291
Gamage, S. D., Patton, A. K., Hanson, J. F. and Weiss, A. A. (2004) Diversity and host range of Shiga toxin-encoding phage. Infect. Immun., 72, 7131–7139
Krylov, V. N. (2001) Phagotherapy in terms of bacteriophage genetics: hopes, perspectives, safety, limitations. Genetika, 37, 869–887
Jerne, N. K. and Avegno, P. (1956) The development of the phageinactivating properties of serum during the course of specific immunization of an animal: reversible and irreversible inactivation. J. Immunol., 76, 200–208
Hodyra-Stefaniak, K., Miernikiewicz, P., Drapała, J., Drab, M., Jończyk-Matysiak, E., Lecion, D., Kaźmierczak, Z., Beta, W., Majewska, J., Harhala, M., et al. (2015) Mammalian Host-Versus-Phage immune response determines phage fate in vivo. Sci. Rep., 5, 14802
Sokoloff, A. V., Zhang, G., Sebestyén, M. G. and Wolff, J. A. (2000) The interactions of peptides with the innate immune system studied with use of T7 phage peptide display. Mol. Ther., 2, 131–139
Merril, C. R., Biswas, B., Carlton, R., Jensen, N. C., Creed, G. J., Zullo, S. and Adhya, S. (1996) Long-circulating bacteriophage as antibacterial agents. Proc. Natl. Acad. Sci. USA, 93, 3188–3192
Vitiello, C. L., Merril, C. R. and Adhya, S. (2005) An amino acid substitution in a capsid protein enhances phage survival in mouse circulatory system more than a 1000-fold. Virus Res., 114, 101–103
Capparelli, R., Ventimiglia, I., Roperto, S., Fenizia, D. and Iannelli, D. (2006) Selection of an Escherichia coli O157:H7 bacteriophage for persistence in the circulatory system of mice infected experimentally. Clin. Microbiol. Infect., 12, 248–253
Capparelli, R., Parlato, M., Borriello, G., Salvatore, P. and Iannelli, D. (2007) Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob. Agents Chemother., 51, 2765–2773
Łusiak-Szelachowska, M., Żaczek, M., Weber-Dąbrowska, B., Międzybrodzki, R., Kłak, M., Fortuna, W., Letkiewicz, S., Rogóż, P., Szufnarowski, K., Jończyk-Matysiak, E., et al. (2014) Phage neutralization by sera of patients receiving phage therapy. Viral Immunol., 27, 295–304
Loc-Carrillo, C. and Abedon, S. T. (2011) Pros and cons of phage therapy. Bacteriophage, 1, 111–114
Hagens, S. and Bläsi, U. (2003) Genetically modified filamentous phage as bactericidal agents: a pilot study. Lett. Appl. Microbiol., 37, 318–323
Hagens, S., Habel, A., von Ahsen, U., von Gabain, A. and Bläsi, U. (2004) Therapy of experimental pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob. Agents Chemother., 48, 3817–3822
Matsuda, T., Freeman, T. A., Hilbert, D. W., Duff, M., Fuortes, M., Stapleton, P. P. and Daly, J. M. (2005) Lysis-deficient bacteriophage therapy decreases endotoxin and inflammatory mediator release and improves survival in a murine peritonitis model. Surgery, 137, 639–646
Westwater, C., Kasman, L. M., Schofield, D. A., Werner, P. A., Dolan, J. W., Schmidt, M. G. and Norris, J. S. (2003) Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob. Agents Chemother., 47, 1301–1307
Moradpour, Z., Sepehrizadeh, Z., Rahbarizadeh, F., Ghasemian, A., Yazdi, M. T. and Shahverdi, A. R. (2009) Genetically engineered phage harbouring the lethal catabolite gene activator protein gene with an inducer-independent promoter for biocontrol of Escherichia coli. FEMS Microbiol. Lett., 296, 67–71
Kasman, L. M., Kasman, A., Westwater, C., Dolan, J., Schmidt, M. G. and Norris, J. S. (2002) Overcoming the phage replication threshold: a mathematical model with implications for phage therapy. J. Virol., 76, 5557–5564
Krom, R. J., Bhargava, P., Lobritz, M. A. and Collins, J. J. (2015) Engineered phagemids for nonlytic, targeted antibacterial therapies. Nano Lett., 15, 4808–4813
Tamma, P. D., Cosgrove, S. E. and Maragakis, L. L. (2012) Combination therapy for treatment of infections with gram-negative bacteria. Clin. Microbiol. Rev., 25, 450–470
Gaj, T., Gersbach, C. A. and Barbas, C. F. III (2013) ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol., 31, 397–405
Citorik, R. J., Mimee, M. and Lu, T. K. (2014) Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat. Biotechnol., 32, 1141–1145
Bikard, D., Euler, C., Jiang, W., Nussenzweig, P. M., Goldberg, G. W., Duportet, X., Fischetti, V. A. and Marraffini, L. A. (2014) Development of sequence-specific antimicrobials based on programmable CRISPRCas nucleases. Nat. Biotechnol., 32, 1146–1150
Yosef, I., Manor, M., Kiro, R. and Qimron, U. (2015) Temperate and lytic bacteriophages programmed to sensitize and kill antibioticresistant bacteria. Proc. Natl. Acad. Sci. USA, 112, 7267–7272
Yacoby, I., Bar, H. and Benhar, I. (2007) Targeted drug-carrying bacteriophages as antibacterial nanomedicines. Antimicrob. Agents Chemother., 51, 2156–2163
Lu, T. K. and Collins, J. J. (2009) Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc. Natl. Acad. Sci. USA, 106, 4629–4634
Edgar, R., Friedman, N., Molshanski-Mor, S. and Qimron, U. (2012) Reversing bacterial resistance to antibiotics by phage-mediated delivery of dominant sensitive genes. Appl. Environ. Microbiol., 78, 744–751
Libis, V. K., Bernheim, A. G., Basier, C., Jaramillo-Riveri, S., Deyell, M., Aghoghogbe, I., Atanaskovic, I., Bencherif, A. C., Benony, M., Koutsoubelis, N., et al. (2014) Silencing of antibiotic resistance in E. coli with engineered phage bearing small regulatory RNAs. ACS Synth. Biol., 3, 1003–1006
Bárdy, P., Pantůček, R., Benešík, M. and Doškař, J. (2016) Genetically modified bacteriophages in applied microbiology. J. Appl. Microbiol., 121, 618–633
Frey, J. (2007) Biological safety concepts of genetically modified live bacterial vaccines. Vaccine, 25, 5598–5605
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm293952.htm
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002617/WC500158413.pdf
Acknowledgments
This work was supported by the Bill and Melinda Gates Foundation under the Grand Challenges Explorations grant (OPP1139488).
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is dedicated to the Special Collection of Synthetic Biology, Aiming for Quantitative Control of Cellular Systems (Eds. Cheemeng Tan and Haiyan Liu).
This article is published with open access at springerlink.fh-diploma.de and journal.hep.com.cn
Rights and permissions
OPEN ACCESS This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Brown, R., Lengeling, A. & Wang, B. Phage engineering: how advances in molecular biology and synthetic biology are being utilized to enhance the therapeutic potential of bacteriophages. Quant Biol 5, 42–54 (2017). https://doi.org/10.1007/s40484-017-0094-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40484-017-0094-5